Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:protein
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
880266-57-9
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:EMD_Serono
gptkb:Merck_KGaA |
| gptkbp:hasINN |
gptkb:atacicept
|
| https://www.w3.org/2000/01/rdf-schema#label |
atacicept
|
| gptkbp:intendedForTreatmentOf |
gptkb:systemic_lupus_erythematosus
multiple sclerosis B-cell mediated diseases |
| gptkbp:macromoleculeType |
recombinant fusion protein
|
| gptkbp:mechanismOfAction |
blocks BLyS and APRIL
inhibits B-cell activation |
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:status |
investigational
|
| gptkbp:target |
B-cell survival factors
|
| gptkbp:targetOfDrug |
gptkb:APRIL
gptkb:BLyS |
| gptkbp:UNII |
6QY1D43K2P
|
| gptkbp:bfsParent |
gptkb:BAFF
|
| gptkbp:bfsLayer |
7
|